Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib

N Engl J Med. 2015 Mar 26;372(13):1189-91. doi: 10.1056/NEJMp1500526.

Authors

Banu A Karimi-Shah¹, Badrul A Chowdhury

Affiliation

¹ From the Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.

PMID: 25806913
DOI: 10.1056/NEJMp1500526

No abstract available

MeSH terms

Advisory Committees
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Cause of Death
Drug Approval*
Enzyme Inhibitors / pharmacology
Enzyme Inhibitors / therapeutic use
Humans
Idiopathic Pulmonary Fibrosis / drug therapy*
Idiopathic Pulmonary Fibrosis / mortality
Idiopathic Pulmonary Fibrosis / physiopathology
Indoles / pharmacology*
Indoles / therapeutic use
Pyridones / pharmacology*
Pyridones / therapeutic use
United States
United States Food and Drug Administration
Vital Capacity / drug effects*

Substances

Anti-Inflammatory Agents, Non-Steroidal
Enzyme Inhibitors
Indoles
Pyridones
pirfenidone
nintedanib